Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00

АШУҮИС — Судалгааны мэдээлэл (CRIS)

Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001

Browse

Search Results

Now showing 1 - 2 of 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Antiviral Efficacy and Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B
    (Mongolian National University of Medical Sciences, 2020-12-29) ;
    Amaraa Ravdan
    ;
    Gegeebadrakh Baljinnyam
    ;
    Burmaajav Badrakh
    ;
    Objectives: To provide compare of the efficacy and safety tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative and HBeAg-positive chronic hepatitis B. Methods: We performed a randomized, unblinded, non-inferiority study in which patients with compensated cirrhosis (Child-Pugh A and B stage) between 18-70 years old with a positive chronic hepatitis B test were randomized to receive either TAF, TDF, or were switched from TDF to TAF. The primary efficacy endpoint was the proportion of patients with HBV-DNA < 29 IU/ml at week 48. Results: The efficacy endpoint, an HBV-DNA < 29 IU/ ml at weeks 48, was achieved by 251 (79.9 %) of 314 patients receiving TAF, which was not significantly different from the 113 (74.8 %) of 151 patients receiving TDF. After 48 weeks of treatment, patients receiving TAF had significantly smaller bone mineral density reductions than patients receiving TDF. At week 48, the median decrease in eGFR was significantly less in the TAF recipients than the TDF recipients. Conclusion: TAF treatment has the same efficacy as TDF treatment. However, TAF treatment had a better safety profile than TDF. Patients receiving TAF had a significantly smaller median decrease in the eGFR by the Cockcroft-Gault equation than patients receiving TDF.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Osteoporosis in Mongolian Population: Prevalence and Risk Factors
    (Mongolian National University of Medical Sciences, 2017-11-25) ; ; ; ;
    Objectives: The purpose of this study was to evaluate the prevalence of osteoporosis and investigate some of its risk factors among Mongolian adults. Methods: The subjects comprised of 2001 adults (age ranged from 20 to 87) were recruited from 5 ecological zones of Mongolia. After applying exclusion criteria, 1990 subjects were selected. Speed of sound (SOS) ultrasonic bone mineral density was measured in the distal one third of radius of the non-dominant arm using the Sunlight Omnisense (Sunlight Medical, Rehovot, Israel). The data were used to calculate mean SOS and T-score by WHO osteoporosis criteria. Results: The average age was 49.1±13.5 (men: 48.6±14.6, women: 49.4±13.0). The prevalence of osteoporosis in men and women from 20-35 years of age was 4.7% vs 6.2%, from 36-45 years of age was 7.2% vs 8.0%, from ages 46-55 was 11.4% vs 25.5%, from ages 56-65 was 21.9% vs 58.3%, and from those over 65 years of age was 35.6% vs 75.5%. The prevalence of osteoporosis was lowest in Ulaanbaatar city. The independent predictors of osteoporosis in Mongolian adults were female sex, menopause, lower education level, physical inactivity and low BMI (BMI<18.5). Conclusion: Compared to neighboring and industrialized countries, the prevalence of osteoporosis in Mongolia is significantly higher. Female sex, lack of exercise, lower education level, menopause and being underweight were identified as risk factors in Mongolian adults.